Recital 4, Regulation (EU) 2026/743

In forcesince 30 Mar 2026

Upon request from the Commission, the Authority adopted a scientific opinion on 29 January 2025 on the nutritional safety and suitability of that specific protein hydrolysate in infant and follow-on formula [EFSA NDA Panel (2025), ‘Nutritional safety and suitability of a specific protein hydrolysate derived from sources of skimmed cow’s milk and whey protein concentrates and used in infant and follow-on formula manufactured from hydrolysed protein by Healthcare Reckitt B.V.’, https://doi.org/10.2903%2Fj.efsa.2025.9278.]. In that opinion, the Authority concluded that the specific protein hydrolysate as described in the opinion is a nutritionally safe and a suitable protein source for use in infant and follow-on formula, as long as the formula in which it is used contains a minimum of 0,55 g/100 kJ (2,3 g/100 kcal) protein and complies with the remaining compositional criteria set out in Delegated Regulation (EU) 2016/127 and with the amino acid pattern contained in Section A of Annex III to that Delegated Regulation.